Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2016
Pharma News, 2016
Exclusive: Lonza in bid to acquire Catalent
Swiss specialty chemicals and life sciences company Lonza Group AG (LONN.
Increase in coffee consumption could provide protective effect in non-alcoholic fatty liver disease
April 13, 2016, Barcelona, Spain.
China says 202 detained in vaccine scandal
A total of 202 people have been detained in connection with a scandal over an illegal black market vaccine ring, the Chinese government said on Wednesday, as it vowed to improve supervision of the mar...
Tech billionaire donates $250 mn for cancer 'moonshot'
Tech billionaire Sean Parker announced Wednesday a $250 million grant to fund research aimed at breakthroughs in cancer treatment through immunotherapy.
FDA panel votes against approving Clovis's cancer drug on current data
(Reuters) - An independent panel of experts advising the U.
Traditional Chinese Herb Eyed For Cancer And Liver Disease Treatment
Wogonin ...
Mylan announces US launch of Generic Lopressor Tablets 37.5 mg and 75 mg
Mylan announced the U.
B-School innovation professor discovers pathway between diabetes and Alzheimer's disease
New York, NY, April 12, 2016.
USPSTF: Final Guidelines on Aspirin as CVD, Cancer Prevention
People aged 50 to 69 years who have a 10% or greater 10-year risk for cardiovascular disease (CVD) and who do not have higher risk for bleeding should consider taking low-dose aspirin to h...
AbbVie/Roche drug gets U.S. approval for a rare type of leukemia
AbbVie Inc won U.
Sun Pharma obtains US FDA approval for BromSite
The US Food and Drug Administration (FDA) has given its approval for Sun Pharma's eye inflammation drug BromSite (bromfenac ophthalmic solution).
Ridding U.S. of hepatitis B, C as 'public health problem' possible: Experts
MONDAY, April 11, 2016 -- Experts say there's real hope in someday ridding the United States of the "public health problem" of hepatitis B and C infection.
40
41
42
43
44
45
46
47
48
